1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
insider
insider
Articles 

Camber Capital Management LLC Buys Allergan PLC, Myriad Genetics, Vertex Pharmaceuticals, Sells The Medicines Co, Community Health Systems, Valeant Pharmaceuticals International

Boston, MA, based Investment company Camber Capital Management LLC buys Allergan PLC, Myriad Genetics, Vertex Pharmaceuticals, LivaNova PLC, Biogen, Abbott Laboratories, Nektar Therapeutics, athenahealth, Gilead Sciences, Brookdale Senior Living, sells The Medicines Co, Community Health Systems, Valeant Pharmaceuticals International, PTC Therapeutics, Arena Pharmaceuticals during the 3-months ended 2016-12-31, according to the most recent filings of the investment company, Camber Capital Management LLC. As of 2016-12-31, Camber Capital Management LLC owns 35 stocks with a total value of $1.9 billion. These are the details of the buys and sells.

For the details of Camber Capital Management LLC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Camber+Capital+Management+LLC

These are the top 5 holdings of Camber Capital Management LLC
  1. Teva Pharmaceutical Industries Ltd (TEVA) - 4,724,450 shares, 9.16% of the total portfolio. Shares added by 18.11%
  2. Mylan NV (MYL) - 4,145,889 shares, 8.46% of the total portfolio. Shares added by 7.05%
  3. Stryker Corp (SYK) - 1,000,000 shares, 6.41% of the total portfolio.
  4. Allergan PLC (AGN) - 543,000 shares, 6.1% of the total portfolio. New Position
  5. Gilead Sciences Inc (GILD) - 1,500,000 shares, 5.74% of the total portfolio. Shares added by 25.00%
New Purchase: Allergan PLC (AGN)

Camber Capital Management LLC initiated holdings in Allergan PLC. The purchase prices were between $188.47 and $242.65, with an estimated average price of $207.16. The stock is now traded at around $239.49. The impact to the portfolio due to this purchase was 6.1%. The holdings were 543,000 shares as of 2016-12-31.

New Purchase: Myriad Genetics Inc (MYGN)

Camber Capital Management LLC initiated holdings in Myriad Genetics Inc. The purchase prices were between $16.26 and $21.35, with an estimated average price of $18.09. The stock is now traded at around $19.06. The impact to the portfolio due to this purchase was 3.62%. The holdings were 4,060,000 shares as of 2016-12-31.

New Purchase: Vertex Pharmaceuticals Inc (VRTX)

Camber Capital Management LLC initiated holdings in Vertex Pharmaceuticals Inc. The purchase prices were between $72.02 and $95.36, with an estimated average price of $81.37. The stock is now traded at around $93.97. The impact to the portfolio due to this purchase was 2.95%. The holdings were 750,000 shares as of 2016-12-31.

New Purchase: LivaNova PLC (LIVN)

Camber Capital Management LLC initiated holdings in LivaNova PLC. The purchase prices were between $41.35 and $60.44, with an estimated average price of $49.13. The stock is now traded at around $49.86. The impact to the portfolio due to this purchase was 2.89%. The holdings were 1,200,000 shares as of 2016-12-31.

New Purchase: Biogen Inc (BIIB)

Camber Capital Management LLC initiated holdings in Biogen Inc. The purchase prices were between $251.91 and $298.81, with an estimated average price of $273.04. The stock is now traded at around $282.41. The impact to the portfolio due to this purchase was 2.41%. The holdings were 175,000 shares as of 2016-12-31.

New Purchase: Abbott Laboratories (ABT)

Camber Capital Management LLC initiated holdings in Abbott Laboratories. The purchase prices were between $37.6 and $43.5, with an estimated average price of $39.65. The stock is now traded at around $45.03. The impact to the portfolio due to this purchase was 2.05%. The holdings were 1,000,000 shares as of 2016-12-31.

Added: Nektar Therapeutics Inc (NKTR)

Camber Capital Management LLC added to the holdings in Nektar Therapeutics Inc by 87.50%. The purchase prices were between $11.85 and $17.48, with an estimated average price of $13.55. The stock is now traded at around $15.66. The impact to the portfolio due to this purchase was 1.84%. The holdings were 6,000,000 shares as of 2016-12-31.

Added: Gilead Sciences Inc (GILD)

Camber Capital Management LLC added to the holdings in Gilead Sciences Inc by 25.00%. The purchase prices were between $71.61 and $78.47, with an estimated average price of $74.33. The stock is now traded at around $68.70. The impact to the portfolio due to this purchase was 1.15%. The holdings were 1,500,000 shares as of 2016-12-31.

Added: Brookdale Senior Living Inc (BKD)

Camber Capital Management LLC added to the holdings in Brookdale Senior Living Inc by 37.50%. The purchase prices were between $11.27 and $17.59, with an estimated average price of $13.42. The stock is now traded at around $12.22. The impact to the portfolio due to this purchase was 1%. The holdings were 5,500,000 shares as of 2016-12-31.

Added: Endologix Inc (ELGX)

Camber Capital Management LLC added to the holdings in Endologix Inc by 263.50%. The purchase prices were between $5.27 and $13.21, with an estimated average price of $9.16. The stock is now traded at around $6.46. The impact to the portfolio due to this purchase was 0.8%. The holdings were 3,635,000 shares as of 2016-12-31.

Sold Out: The Medicines Co (MDCO)

Camber Capital Management LLC sold out the holdings in The Medicines Co. The sale prices were between $30.88 and $38.51, with an estimated average price of $35.47.

Sold Out: Community Health Systems Inc (CYH)

Camber Capital Management LLC sold out the holdings in Community Health Systems Inc. The sale prices were between $4.66 and $11.47, with an estimated average price of $6.94.

Sold Out: Valeant Pharmaceuticals International Inc (VRX)

Camber Capital Management LLC sold out the holdings in Valeant Pharmaceuticals International Inc. The sale prices were between $13.6 and $24.59, with an estimated average price of $18.34.

Sold Out: PTC Therapeutics Inc (PTCT)

Camber Capital Management LLC sold out the holdings in PTC Therapeutics Inc. The sale prices were between $4.19 and $13.71, with an estimated average price of $10.49.

Sold Out: Protalix BioTherapeutics Inc (PLX)

Camber Capital Management LLC sold out the holdings in Protalix BioTherapeutics Inc. The sale prices were between $0.29 and $0.57, with an estimated average price of $0.45.

Reduced: Arena Pharmaceuticals Inc (ARNA)

Camber Capital Management LLC reduced to the holdings in Arena Pharmaceuticals Inc by 59.52%. The sale prices were between $1.35 and $1.86, with an estimated average price of $1.55. The stock is now traded at around $1.56. The impact to the portfolio due to this sale was -0.5%. Camber Capital Management LLC still held 4,250,000 shares as of 2016-12-31.



Here is the complete portfolio of Camber Capital Management LLC. Also check out:

1. Camber Capital Management LLC's Undervalued Stocks
2. Camber Capital Management LLC's Top Growth Companies, and
3. Camber Capital Management LLC's High Yield stocks
4. Stocks that Camber Capital Management LLC keeps buying

Rating: 0.0/5 (0 votes)

Comments

Please leave your comment:


GuruFocus has detected 3 Warning Signs with Nektar Therapeutics Inc $NKTR.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.

Performances of the stocks mentioned by insider


User Generated Screeners


nghassanPenny Stocks
Numanchucode:5
brucexrog jun 2017
clemclem_99GuVGain3
PortfolioPlusMy Oceania Universe
PortfolioPlusMy Universe
clemclem_99GuVGain2
WellrossHELLOJUNE
clemclem_99GuVGain1
danvillescottBANKS
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK